Thrombopoietin
- Generic Name
- Thrombopoietin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9014-42-0
- Unique Ingredient Identifier
- 5651J3R2JF
- Indication
Investigated for use/treatment in thrombocytopenia.
- Associated Conditions
- -
- Associated Therapies
- -
New blood test can predict how long vaccine immunity will last
A new blood test identifies a molecular signature predicting vaccine immunity duration, linked to megakaryocytes and platelet RNA. This breakthrough could enhance vaccine development, personalize vaccination plans, and expedite clinical trials by forecasting vaccine durability early post-vaccination.
FDA accepts Sobi North America's thrombocytopenia therapy sNDA
FDA accepted Sobi North America's sNDA for avatrombopag (DOPTELET) to treat paediatric immune thrombocytopenia in children aged one and above. Supported by AVA-PED-301 trial data, it aims to address unmet needs with an oral suspension option. Sobi, planning to acquire CTI BioPharma, moves closer to offering new ITP treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath